Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 3,504 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult-Onset Diabetes Mellitus Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Markers of Early Pancreas Cancer

NCT03568630
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, PreDiabetes, Pancreas Cyst, Chronic Pancreatitis, Genetic Predisposition to Disease, Inherited Disease
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 2Phase 3 Interventional

Dose Ranging Study With LT, Monotherapy, PPAR

NCT00240383
View directory record Official record
Conditions
Diabetes Mellitus II
Interventions
Muraglitazar
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
149
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 146 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes

NCT00924053
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
EGT0001474, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 3 Interventional

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

NCT05394519
View directory record Official record
Conditions
Overweight, Obesity, Type 2 Diabetes Mellitus
Interventions
Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
49
States / cities
Concord, California • Escondido, California • Fullerton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

NCT00995930
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 18, 2026, 5:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

NCT06845202
View directory record Official record
Conditions
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
Interventions
ALN-4324, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
7
States / cities
Montclair, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 18, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional

Diabetic Gastroparesis Efficacy/Safety Study of TZP-102

NCT01664637
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
10 mg TZP-102, Placebo
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Huntsville, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Southeastern Diabetes Initiative Clinical Intervention

NCT01965639
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Extension of Care
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Madison, Mississippi • Durham, North Carolina • Kannapolis, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2016 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus

NCT00952445
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
T0903131 Besylate, Placebo
Drug
Lead sponsor
InteKrin Therapeutics, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • Santa Ana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 18, 2026, 5:23 PM EDT
Not listed Phase 3 Interventional

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

NCT01137695
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pramlintide
Drug
Lead sponsor
Cheryl Rosenfeld, DO
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Denville, New Jersey • Staten Island, New York • Langhorne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2011 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Weight Loss-Independent Metabolic Effects of Roux-En-Y Gastric Bypass in Diabetes

NCT02207777
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
Roux-en-Y gastric bypass surgery, Low-calorie diet
Procedure · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT00916357
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bingocize: A Novel Mobile Application for Older Adult Health

NCT03629912
View directory record Official record
Conditions
Activities of Daily Living, Accidental Fall, Sarcopenia, Arteriosclerosis, Diabetes Mellitus, Type 2, Hypertension, Cognitive Decline, Executive Function, Cognitive Aging
Interventions
Socially-Based Exercise Intervention for Older Adults
Behavioral
Lead sponsor
Western Kentucky University
Other
Eligibility
60 Years to 85 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
4
States / cities
Dixon, Kentucky • Henderson, Tennessee • Johnson City, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 3 Interventional

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

NCT06066528
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2
Interventions
Survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
34
States / cities
Anniston, Alabama • Phoenix, Arizona • Spring Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

NCT02607865
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, sitagliptin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Tuscumbia, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Low Dose Fat-Induced Insulin Resistance

NCT03479671
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance, Insulin Sensitivity
Interventions
Intralipid, 20% Intravenous Emulsion
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 44 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

Diabetes Care for Breast Cancer Patients

NCT05565534
View directory record Official record
Conditions
Breast Cancer, PreDiabetes, Type 2 Diabetes
Interventions
Nurse-practitioner led intervention
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Brooklyn, New York • Flushing, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 18, 2026, 5:23 PM EDT
Not listed Not applicable Interventional

Pathway for Produce Prescriptions in Diabetes Management

NCT06058338
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Produce Prescription
Behavioral
Lead sponsor
Gretchen Swanson Center for Nutrition
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Fort Wayne, Indiana • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 3 Interventional

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency

NCT00616811
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin, Sitagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 85 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
79
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 18, 2026, 5:23 PM EDT
Completed No phase listed Observational

Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data

NCT07599293
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Chronic Heart Failure, Type 2 Diabetes Mellitus
Interventions
Empagliflozin, Sitagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
39,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 4 Interventional

24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine

NCT00551538
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lispro mix 75/25, Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes

NCT00871936
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
SLx-4090, Placebo, Metformin
Drug · Other
Lead sponsor
Response Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Anaheim, California • Burbank, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 18, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver

NCT00323414
View directory record Official record
Conditions
Fatty Liver
Interventions
Polyunsaturated fatty acid (Opti-EPA), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 18, 2026, 5:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Preclinical Imaging Biomarkers of Alzheimer's Disease Neuropathology in Young Adults With Youth-onset Diabetes: a Proof-of-concept Study

NCT05350514
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes, Youth Onset
Interventions
PI-2620 tracer
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 18, 2026, 5:23 PM EDT